OneMedNet Corporation ONMD PHARMA
Company Overview
OneMedNet Corporation, a healthcare software company, provides digital medical image management, exchange, and sharing solutions in the Americas, Europe, and the Middle East. It offers iRWD, which provides regulatory grade imaging and clinical data in the pharmaceutical, device manufacturing, contract research organizations, and artificial intelligence markets markets. The company also provides BEAM, a medical imaging exchange platform between hospital/healthcare systems, imaging centers, physicians, and patients. OneMedNet Corporation is headquartered in Eden Prairie, Minnesota.
Why Investors Should Care
Generates a return on equity of 94.5%, reflecting efficient use of shareholder capital.
Recent Developments
- Dec 2025 Revenue of $1.36M (+111.4% YoY); net profit $-2.80M.
- Trailing 12 Months Year-on-year growth — revenue +88.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.63% |
| 1 Year: | 88.40% |
Stock Price Performance
| 1 Year: | +42.85% |
| 6 Months: | -0.91% |
| 3 Months: | -0.62% |
| 1 Month: | +9.71% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)57.36 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 94.5%.
CONS
- Trading 78.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ONMD OneMedNet Corporation PHARMA | 0.69 | -4.06 | $40.91M | 0.00% | - | 94.47% | 5.63% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 200.00K | 173.00K | 326.00K | 248.00K | 227.00K | 142.00K | - | 137.00K | 155.00K | 177.00K | 891.00K | 96.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 361.00K | 396.00K | 399.00K | 726.00K | 476.00K |
| Gross Profit | - | - | - | - | - | -89.00K | -57.00K | 33.00K | -69.00K | -102.00K | -84.00K | - | -224.00K | -241.00K | -222.00K | 165.00K | -380.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 2.00M | 1.82M | 2.01M | 3.25M | 2.17M |
| Operating Income | -70.49K | -98.72K | -610.18K | -794.50K | -520.02K | -1.47M | -1.57M | -1.93M | -2.10M | -2.45M | -2.34M | - | -2.22M | -2.06M | -2.23M | -3.08M | -2.55M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -1.86M | 3.04M | -725.00K | -3.12M | -2.43M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 31.00K | 22.00K | 6.00K | 8.00K | 10.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -1.90M | 2.98M | -741.00K | -3.14M | -2.45M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | 4.31M | 1.29M | 2.20M | 949.94K | -153.28K | -7.84M | -9.60M | -13.84M | -2.11M | -3.59M | -2.06M | - | -1.90M | 2.98M | -741.00K | -3.14M | -2.45M |
| Diluted EPS | - | - | - | - | - | -1.94 | -2.38 | -3.23 | -0.08 | -0.14 | -0.07 | - | -0.06 | 0.07 | -0.01 | - | -0.04 |
| R&D Expense | - | - | - | - | - | 582.00K | 579.00K | 405.00K | 445.00K | 383.00K | 298.00K | - | 348.00K | 382.00K | 323.00K | - | 311.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 1.15M | 1.02M | 643.00K | 1.36M |
| Cost of Revenue | - | 1.51M | 1.15M | 924.00K | 1.86M |
| Gross Profit | - | -360.00K | -129.00K | -281.00K | -503.00K |
| Operating Expenses | - | 15.43M | 6.72M | 9.32M | 9.16M |
| Operating Income | - | -15.79M | -6.85M | -9.61M | -9.67M |
| EBITDA | - | -30.41M | -33.72M | -9.92M | -2.67M |
| Interest Expense | - | 0 | 11.00K | 147.00K | 67.00K |
| Pretax Income | - | -30.43M | -33.76M | -10.13M | -2.80M |
| Tax Provision | - | 17.00K | 18.00K | 2.00K | 1.00K |
| Net Income | - | -30.45M | -33.78M | -10.13M | -2.80M |
| Diluted EPS | - | -7.55 | -4.65 | -0.36 | -0.06 |
| R&D Expense | - | 952.70K | 2.06M | 1.47M | 1.51M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Feb 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.29M | 464.00K | 3.73M | 2.15M |
| Current Assets | - | - | 391.00K | 365.00K | 3.62M | 2.10M |
| Cash & Equivalents | - | - | 271.00K | 47.00K | 172.00K | 585.00K |
| Inventory | - | - | - | - | - | - |
| Receivables | - | - | 19.00K | 152.00K | 213.00K | 495.00K |
| Total Liabilities | - | - | 27.65M | 13.91M | 19.68M | 5.12M |
| Current Liabilities | - | - | 26.10M | 13.84M | 19.23M | 4.83M |
| Long Term Debt | - | 1.55M | 1.50M | 465.00K | - | 220.00K |
| Total Debt | - | - | 26.24M | 5.09M | 8.76M | 570.00K |
| Total Equity | 0 | - | -26.36M | -13.44M | -15.95M | -2.96M |
| Shares Outstanding | - | - | 32.26M | 23.57M | 28.18M | 52.17M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -4.70M | -4.79M | -6.95M | -7.50M |
| Investing Cash Flow | - | -58.00K | -44.00K | -1.98M | 2.31M |
| Financing Cash Flow | - | 4.33M | 4.61M | 9.06M | 5.61M |
| Capital Expenditure | - | -58.00K | -44.00K | -51.00K | -13.00K |
| Free Cash Flow | - | -4.76M | -4.83M | -7.00M | -7.52M |
| Net Change in Cash | - | -428.00K | -224.00K | 125.00K | 413.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | -31.2% | -12.6% | -43.7% | -37.0% |
| Operating Margin % | - | -1,369.3% | -671.2% | -1,493.8% | -711.3% |
| Net Margin % | - | -2,641.0% | -3,308.5% | -1,575.3% | -206.1% |
| ROE % | - | 115.5% | 251.3% | 63.5% | 94.5% |
| ROCE % | - | 63.6% | 51.2% | 62.0% | 361.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Savant Capital LLC | 12.18% | 7.22M | $5.05M |
| 2 | Vanguard Capital Management LLC | 1.94% | 1.15M | $806.55K |
| 3 | Geode Capital Management, LLC | 0.56% | 334.33K | $234.03K |
| 4 | Vanguard Fiduciary Trust Co | 0.23% | 137.71K | $96.39K |
| 5 | Blackrock Inc. | 0.20% | 120.98K | $84.69K |
| 6 | State Street Corporation | 0.20% | 116.70K | $81.69K |
| 7 | Discovery Capital Management, LLC | 0.19% | 112.25K | $78.58K |
| 8 | PNC Financial Services Group, Inc. | 0.17% | 103.33K | $72.33K |
| 9 | Openarc Corporate Advisory, LLC | 0.16% | 97.41K | $68.19K |
| 10 | Northern Trust Corporation | 0.08% | 46.84K | $32.78K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ONMD
OneMedNet’s data network spans more than 90 million patient journeys for AI drug development - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQYm1PdVZDS0pEWnNIVmhFZzJUcFh2U2hhWU43T2swUV9CUjFZWEU2UkRDWEkzVFRldDF1MkNqdEYwMS1xNU43N0FCRkZDRmZIZ0NKWk5Zc1RwaU95X0s4ZlRHU1ZHM2tZU0ROTHZXX1kwY09PLS1zeTJOb2lOdEUtNTdnN1BGUFF1TlBmYm…
OneMedNet Company Profile & Introduction - Moomoo
<a href="https://news.google.com/rss/articles/CBMikANBVV95cUxPelY2ME9jeG5pMTA4ZEdIN0VBNHdnM3p2aXQxUlNQVWtJSU96UmpNRGJOcXc4a1RSejBpM3Q5MmtxSVV0RlhRV1YzM3pxeDhlM1hHQUN2N2ZpMDN4bWw5NERDb1hsMmJveG1OMDdlLVNHemVzNDd1ZGctYW9ISVAxNGZRSXp3eDJOazhIMm…
OneMedNet Corp. (NASDAQ: ONMD) Stock Price, News & Analysis - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE9hbzNBaFlGalUxb1ZOVE90Z0JKOWN1NGJiQ3k4VEhWUDdqd0laaHExaVJNX1NnZnEwM0pDMnE3bzhzLXY1NDhWSlotMjhqTHdzRnYzeXVn?oc=5" target="_blank">OneMedNet Corp. (NASDAQ: ONMD) Stock Price, News & …
OneMedNet Corp. (NASDAQ: ONMD) Stock Price, News & Analysis - kalkine.ca
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1xNkJod1p3S2twRlJUUXF6bGg5N3A2N1Y5RHBVR05MX2pVR3lJUXN1Z01KSFhWeWdXTFAtWmZlSVJZaDREXzAtVjh0dFNjSzZX?oc=5" target="_blank">OneMedNet Corp. (NASDAQ: ONMD) Stock Price, News & Analysis…
ONMD - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9YUkxlcXhaUGpmYVg5a3VySElXYUtDQjdKQmZLUjAxUGpBa203aTB3R3NGUWY4ZnFwTVEwczJjNDJnZVJINWc?oc=5" target="_blank">ONMD</a> <font color="#6f6f6f">Finviz</font>…
$ONMD stock is up 26% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOVGhJTHRfQk5DWTFsWk01RGNOYWRGM05Ca3pMNEJOSEVDLUZXdDA2TmN5M3hQVGgySFRjdFg1QXphTTBJOEN4QTdxdEZaZEpGQWo4dGlXbVdvNVhJOWZUbkJTUlJuVEMtTUFMRWVLNW5IU2x5aXA2YVBDLVdFd1o4R3U0OXA4clNiSzUzRT…
ONMD — Frequently Asked Questions
What is the current share price of OneMedNet Corporation (ONMD)?
As of 2026-09-19 21:16 PDT, OneMedNet Corporation (ONMD) trades at $0.69 on NasdaqCM. Its 52-week range is $0.48 to $3.14.
What is the market capitalisation of ONMD?
OneMedNet Corporation (ONMD) has a market capitalisation of $40.91M on NasdaqCM.
What is the P/E ratio of ONMD?
ONMD trades at a trailing price-to-earnings (P/E) ratio of -4.06. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -11.48.
What is the return on equity (ROE) of ONMD?
ONMD has a return on equity (ROE) of 94.47%.
Is ONMD a good stock to buy?
This page provides a data-driven analysis of OneMedNet Corporation (ONMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.